---
document_datetime: 2024-04-10 09:20:33
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/abilify-maintena-epar-all-authorised-presentations_en.pdf
document_name: abilify-maintena-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.7781037
conversion_datetime: 2025-12-28 12:11:55.136667
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                                               | Route of Administration   | Immediate Packaging                         | Content (concentration)         | Pack size                                                                                                                                                        |
|------------------|-------------------|------------|-------------------------------------------------------------------|---------------------------|---------------------------------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EU/1/13/882/001  | Abilify Maintena  | 300 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | powder: vial (glass); solvent: vial (glass) | powder: 300 mg; solvent: 2 ml   | 1 powder vial + 1 solvent vial + 1 syringe with pre- attached needle + 1 disposable syringe with luer lock tip + 1 vial adaptor + 3                              |
| EU/1/13/882/002  | Abilify Maintena  | 400 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | powder: vial (glass); solvent: vial (glass) | powder: 400 mg; solvent: 2 ml   | needles 1 powder vial + 1 solvent vial + 1 syringe with pre- attached needle + 1 disposable syringe with luer lock tip + 1 vial adaptor + 3                      |
| EU/1/13/882/003  | Abilify Maintena  | 300 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | powder: vial (glass); solvent: vial (glass) | powder: 300 mg; solvent: 2 ml   | 3 (3 x [1 powder vial + 1 solvent vial + 1 syringe with pre-attached needle + 1 disposable syringe with luer lock tip + 1 vial                                   |
| EU/1/13/882/004  | Abilify Maintena  | 400 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | powder: vial (glass); solvent: vial (glass) | powder: 400 mg; solvent: 2 ml   | (multipack) 3 (3 x [1 powder vial + 1 solvent vial + 1 syringe with pre-attached needle + 1 disposable syringe with luer lock tip + 1 vial adaptor + 3 needles]) |
| EU/1/13/882/005  | Abilify Maintena  | 300 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | dual-chamber pre-filled syringe (glass)     | powder: 300 mg; solvent: 1.2 ml | (multipack) 1 pre-filled syringe + 3 needles                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                                               | Route of Administration   | Immediate Packaging                     | Content (concentration)         | Pack size                                              |
|------------------|-------------------|------------|-------------------------------------------------------------------|---------------------------|-----------------------------------------|---------------------------------|--------------------------------------------------------|
| EU/1/13/882/006  | Abilify Maintena  | 400 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | dual-chamber pre-filled syringe (glass) | powder: 400 mg; solvent: 1.6 ml | 1 pre-filled syringe + 3 needles                       |
| EU/1/13/882/007  | Abilify Maintena  | 300 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | dual-chamber pre-filled syringe (glass) | powder: 300 mg; solvent: 1.2 ml | 3 (3 x [1 pre-filled syringe + 3 needles]) (multipack) |
| EU/1/13/882/008  | Abilify Maintena  | 400 mg     | Powder and solvent for prolonged-release suspension for injection | Intramuscular use         | dual-chamber pre-filled syringe (glass) | powder: 400 mg; solvent: 1.6 ml | 3 (3 x [1 pre-filled syringe + 3 needles]) (multipack) |
| EU/1/13/882/009  | Abilify Maintena  | 720 mg     | Prolonged-release suspension for injection                        | Intramuscular use         | pre-filled syringe (COC)                | 2.4 ml (300 mg/ml)              | 1 pre-filled syringe + 2 needles                       |
| EU/1/13/882/010  | Abilify Maintena  | 960 mg     | Prolonged-release suspension for injection                        | Intramuscular use         | pre-filled syringe (COC)                | 3.2 ml (300 mg/ml)              | 1 pre-filled syringe + 2 needles                       |